Previous 10 | Next 10 |
home / stock / mrk / mrk articles
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and long-term business goals. The compan...
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: ...
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pem...
In the current market session, Merck & Co Inc. (NYSE:MRK) price is at $101.20, after a 0.07% spike. However, over the past month, the stock dec...
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent&n...
BMO Capital Markets analyst Evan David Seigerman reiterated an Outperform rating on Merck & Company, Inc. (NYSE: MRK), with...
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, In...
The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, in combination with fluoropyrimidine- and plati...
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable f...
News, Short Squeeze, Breakout and More Instantly...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the fourth quarter of 2024. Payment will be made on Oct. 7, 2024, to shareholders of r...
2024-07-23 09:30:00 ET The Dow Jones Industrial Average has long been a bellwether for the overall health of the U.S. stock market, tracking 30 large publicly owned companies across various sectors. While the index has seen modest gains in 2024, one of its constituents has been signific...
Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigati...